# FDA 483 - Prithviraj Bose, M.D. - April 30, 2026

Source: https://www.keypedia.com/records/483/prithviraj-bose-md/b24e5054-d63a-4e1d-a659-1bb354b1bd80

> FDA 483 for Prithviraj Bose, M.D. on April 30, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Prithviraj Bose, M.D.
- Inspection Date: 2026-04-30
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West III
- Summary: An FDA inspection of Prithviraj Bose, MD, a Clinical Investigator in Houston, TX, revealed significant deviations from the investigational plan. The primary concern was the failure to ensure subjects met all eligibility criteria before randomization into a study. This included enrolling subjects who did not meet specific inclusion criteria and randomizing a subject before all required screening assessments were complete.

## Related Officers

- [Terri E. Gibson](https://www.keypedia.com/people/terri-e-gibson/f1a80f95-a5c4-4cae-9a4b-e23f367770bb)

Company: https://www.keypedia.com/companies/prithviraj-bose-md/6dd26ac4-71e5-4852-b72e-459373b5fd7f

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-operations-west-iii/2cda09a5-06c4-433f-9df0-0d7903a6efab